Achaogen, Inc. is a clinical-stage biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on AKAO’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Achaogen could be a solid choice for investors.
Current Quarter Estimates for AKAO
In the past 30 days, none of the estimates have gone higher for Achaogen while none have gone lower in the same time period. The trend has been however pretty favorable, with estimates narrowing from a loss of 52 cents a share 30 days ago, to a loss of 47 cents today, a move of 9.6%.
Current Year Estimates for AKAO
Meanwhile, Achaogen’s current year figures are also same, with no estimates moving in either direction in the past month. However, the consensus estimate trend has seen a boost for this time frame also, narrowing from a loss of $2.67 per share 30 days ago to a loss of $2.47 per share today, an increase of 7.5%.
Bottom Line
The stock has also started to move higher lately, adding 178.3% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Best Place to Start Your Stock Search
Today, you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
Image: Bigstock
Earnings Estimates Moving Higher for Achaogen (AKAO): Time to Buy?
Achaogen, Inc. is a clinical-stage biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on AKAO’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Achaogen could be a solid choice for investors.
Current Quarter Estimates for AKAO
In the past 30 days, none of the estimates have gone higher for Achaogen while none have gone lower in the same time period. The trend has been however pretty favorable, with estimates narrowing from a loss of 52 cents a share 30 days ago, to a loss of 47 cents today, a move of 9.6%.
Current Year Estimates for AKAO
Meanwhile, Achaogen’s current year figures are also same, with no estimates moving in either direction in the past month. However, the consensus estimate trend has seen a boost for this time frame also, narrowing from a loss of $2.67 per share 30 days ago to a loss of $2.47 per share today, an increase of 7.5%.
ACHOGEN INC Price and Consensus
ACHOGEN INC Price and Consensus | ACHOGEN INC Quote
Bottom Line
The stock has also started to move higher lately, adding 178.3% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Best Place to Start Your Stock Search
Today, you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>